Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial

May 22, 2026

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Read more

May 21, 2026

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

Read more

May 20, 2026

Study Supports Use of AL, IWT Scores in Amyloidosis

Read more

May 18, 2026

ACC CardiaCast: In Case You Missed It: ACC.26 ATTR-CM Treatment Updates

Read more

May 18, 2026

Phase 3 Study Shows PET Tracer Met Primary Endpoints in Cardiac Amyloidosis Diagnosis

Read more

May 18, 2026

Hereditary transthyretin amyloid cardiomyopathy caused by the rare TTR p.Ser43Asn variant in an Asian family: a case report

Read more

May 18, 2026

Hereditary amyloidosis not linked to increased risk of aortic valve disease

Read more

May 18, 2026

Innovation Developed by UT Health Sciences Research Program Passes Landmark Trial for Cardiac Amyloidosis

Read more

May 15, 2026

Progressive Macroglossia and Dysphagia as the Initial Manifestation of Systemic Amyloid Light-Chain (AL) Amyloidosis Associated With Multiple Myeloma: A Case Report and Literature Review

Read more

May 14, 2026

Invisible No More: Low Awareness, Missed Diagnoses -- New Survey Sheds Light on ATTR-CM's Hidden Impact on Women

Read more

Subscribe to